Company intelligence / Profile preview
YL Biologics Limited
Chuo-ku, Tokyo, Japanylbiologics.co.jp ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
YL Biologics has successfully developed and received PMDA approval for Etanercept biosimilar in Japan. Their biosimilar YLB113 (Etanercept) demonstrated equivalent efficacy and safety to the reference product Enbrel in a global Phase 3 clinical trial. They have also filed an NDA for YLB217, a biosimilar of long-acting erythropoiesis stimulating agent Nesp.
- Therapeutic areas
- DermatologyRheumatologyImmunology
- Modalities
- BiosimilarsMonoclonal Antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Yoshindo Inc.Lupin LimitedLupin Atlantis Holdings SA (LAHSA)Kyowa Pharmaceutical Industry Co. Ltd
Beyond the preview
Go deeper on YL Biologics Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YL Biologics Limited.